potential of any HIV screening program, no matter how enthusiastically and competently that screening program is implemented. The guidelines state, "Screening for HIV infection…would allow for earlier and expanded detection of HIV infection, thus resulting in earlier medical and behavioral interventions and treatment [italics added]." 1 Traversing the continuum from a seropositive test to timely and successful interventions and treatment is neither automatic nor to be taken for granted.
Indeed, the Centers for Disease Control and Prevention currently estimates that among US individuals who are aware of their HIV infection, only 73% are in care, and only 60% are virologically suppressed. 11 The barriers include mental illness, substance use disorder, HIV stigma, and the complexity of the health care system. 12, 13 The USPSTF offers guidance on the perfunctory mechanics of obtaining consent, delivering results, and providing opportunities for questions. Though the USPSTF acknowledges the importance of ART initiation and the potential barriers to services, the document is silent on the less transactional, more delicate aspects of facilitating linkage to care at the time of a positive test-the word linkage does not appear anywhere in the primary recommendations (only in the response to public comment)-despite economic analyses demonstrating that improving linkage is among the most attractive investments to be made in a testing program. 14 Similarly, the USPSTF's description of the potential harms of screening and treatment offers an inventory of ART regimens' adverse effects-cardiovascular, neuropsychiatric, hepatic, renal, and bone-but overlooks the more proximal and care-limiting issues of stigma, gender-based violence, and medical care
coverage. By avoiding these key obstacles along the HIV treatment and prevention cascades, the USPSTF undermines its own recommendation-testing is the beginning, not the end, of the process of addressing HIV as both a public health and clinical issue.
Turning to PrEP, the USPSTF reviews a decade's worth of evidence on efficacy in alternative settings and demographic populations. The US Food and Drug Administration approved the use of emtricitabine/tenofovir for this indication among adults in 2012. The recommendations provide useful guidance on who should be considered a candidate for PrEP, by demographic subgroup (eg, men who have sex with men, heterosexual women, and persons who inject drugs) and by risk (eg, serodiscordant sex partners, recent sexually transmitted infection, and sharing injection equipment).
They also provide references for behavioral counseling, including abstinence, reducing the number of sexual partners, and condom use.
As with its recommendations on HIV testing, the USPSTF focuses on the mechanics of entry.
The document acknowledges stigma and racial/ethnic disparities as barriers to care but refers to Centers for Disease Control and Prevention recommendations for guidance about 2 key obstacles to sustained and successful PrEP implementation: access and adherence. annually. 20 At an annual cost of $20 000 per person, the drug component alone of a complete PrEP rollout for all those eligible would cost $24 billion annually. With generic emtricitabine/tenofovir disoproxil fumarate available soon, affordability will improve, but attempts are already being made to shift prescribing to emtricitabine/tenofovir alafenamide, which will entail higher costs with relatively modest differences in clinical outcomes. 21 The USPSTF has taken an important step in securing access to services that will hasten the end of the HIV epidemic in the United States by 2030. 22, 23 
